DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/n9ngzz/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- BioCryst Pharmaceuticals, Inc.
- Cevec Pharmaceuticals GmbH
- CSL Limited
- Dyax Corp.
- Global Blood Therapeutics, Inc.
- iBio, Inc.
- Isis Pharmaceuticals, Inc.
- Pharming Group N.V.
- Ra Pharmaceuticals, Inc.
- Shire Plc
Drug Profiles
- BCX-4161
- BCX-7353
- BEL-0215
- C1 esterase inhibitor (human)
- C1 esterase inhibitor (recombinant)
- CSL-312
- DX-2930
- icatibant acetate
- ISIS-PKKRx
- Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema
- Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema
- Small Molecule for Hereditary Angioedema
- Synthetic Peptide to Inhibit Kallikrein for Hereditary Angioedema
For more information visit http://www.researchandmarkets.com/research/n9ngzz/hereditary
